Guardant 360® Liquid Biopsy Advances Clinical Trial Enrollment

Dr. Justin Odegaard, VP of Clinical Development at Guardant Health discusses a new study published in "Nature Medicine" (Oct 2020) which finds that the Guardant360® liquid biopsy rapid blood test is not only concordant to tissue biopsy, but more than doubles clinical trial enrollment and achieves similar treatment response and survival rates in patients with advanced gastrointestinal cancer.

#GuadrantHealth #Guadrant360

Visit our website
www.healtprofessionalradio.com.au

Follow us on our social media channels
Facebook: https://www.facebook.com/hprfm/
Twitter: https://twitter.com/HealthProRadio
Google+: https://plus.google.com/+HealthProfes...
Pinterest: https://www.pinterest.com/HealthProRa...
Linkedin: https://www.linkedin.com/company/heal...
Instagram: https://www.instagram.com/healthprofe...

Subscribe to our podcast channels
Soundcloud: https://soundcloud.com/healthprofessi...
Itunes: https://itunes.apple.com/nz/podcast/h...

Support us on Patreon
https://www.patreon.com/HPR

Видео Guardant 360® Liquid Biopsy Advances Clinical Trial Enrollment канала Health Professional Radio